-
When it comes to family planning, more women are choosing long-acting reversible contraception (LARC) methods such as intrauterine devices (IUDs) and the contraceptive implant, say respondents to the 2012 Contraceptive Technology Update Contraception Survey.
-
The upswing of use of long-acting reversible contraception is making an impact on the use of combined oral contraceptives (oCs), according to responses to the 2012 Contraceptive Technology Update Contraception Survey.
-
Birth control sabotage in which a partner deliberately pokes holes in condoms, destroys birth control pills, or tampers with the efficacy of a method is not uncommon.
-
While several protocols are available to start women on a combined oral contraceptive (OC), respondents to the 2012 Contraceptive Technology Update Contraception Survey are firmly behind the Quick Start method of pill initiation.
-
Tubal sterilization is a highly effective, permanent, and safe method of contraception. Tubal sterilization is the second most common method of contraception used by women in the United States and the most common among women over 30 years of age.
-
In this issue: Calcium supplementation in women; type 2 diabetes treatments and pancreatitis risk; treating chronic idiopathic urticaria; rivaroxaban and VTE; and FDA actions.
-
Although the levonorgestrel intrauterine system (LNG IUS) has been shown to be an effective treatment for heavy menstrual bleeding (HMB), previous clinical trials included rigorous criteria focused primarily on measuring the severity of bleeding.
-
During the past few months, there has been a pleth-ora of articles published with important clinical implications, and I have found it difficult to pick just one to review.
-
LAP2 was a phase 3 clinical trial to assess the non-inferiority of laparoscopy compared with laparotomy for recurrence of uterine cancer after surgical staging.
-
This Phase 1 clinical trial evaluated the safety and pharmacokinetics of intraventricular immune-chemotherapy with twice weekly rituximab (10 mg and 25 mg) and methotrexate in 14 patients with recurrent central nervous system lymphoma (primary or secondary).
